Skip to Content
  • Previous Rank
    91
  • Revenues ($M)
    $32,845.10
  • Revenue Percent Change
    6.9%
  • Profits ($M)
    $4.1
  • Profits Percent Change
    -97.6%
  • Assets ($M)
    $11,593.80
  • Employees
    70,430
  • Market Value — as of March 29, 2018 ($M)
    $1,793.40

Dramatic changes are afoot at the third-largest drugstore chain _in the U.S. In 2017, Rite Aid agreed to sell nearly 2,000 pharmacies to Walgreens. And in February, grocery giant Albertsons (No. 53 on the Fortune 500) said it would buy the rest of Rite Aid, creating an $83-billion-in-revenue behemoth, though some shareholders have indicated that they oppose the deal. Rite Aid currently has around 2,600 pharmacies, less than rival chains Walgreens and CVS, but the combined company is expected to have more than 4,000 pharmacies. Plans to generate new revenue involve the merger of rewards programs, in addition to selling Albertsons products in Rite Aid stores.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
John T. Standley
CEO Title
Chairman & Chief Executive Officer
Sector
Food & Drug Stores
Industry
Food and Drug Stores
HQ Location
Camp Hill, Pa.
Websitehttp://www.riteaid.com
Years on Fortune 500 List24
Employees70,430
Figures are for fiscal year ended Feb. 28, 2017.

Rite Aid Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$32,845.106.9%
Profits ($M)$4.1-97.6%
Assets ($M)$11,593.80-
Total Stockholder Equity ($M)$614.1-
Market Value — as of March 29, 2018 ($M)$1,793.40-

Profit Ratios

Profit as % of Revenues0.0%
Profits as % of Assets0.0%
Profits as % of Stockholder Equity0.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)0
EPS % Change (from 2016)-99.9%
EPS % Change (5 year annual rate)-
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2017)-76.1%
Total Return to Investors (5 year, annualized)7.7%
Total Return to Investors (10 year, annualized)-3.4%